Specifically, TriTECM molecules combine T-cell redirection with interleukin-6 receptor (IL-6R) blockade, demonstrating attenuated T-cell activation and reduced interferon-gamma production, which suggests potential for mitigating CRS in clinical settings [145]. Here, IL6R is linked to congenital rubella syndrome.